// App-Quantinova.ai

[SAT0258] : BASELINE MRI/CRP AS PREDICTORS OF RESPONSE TO ETANERCEPT IN THE MANAGEMENT OF PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

Researchers

Presenter

  • M.A. Brown

Principal Investigators

  • P.A. Bird

  • P.C. Robinson

  • P. Mease

  • F. Van den Bosch

  • C. Surian

  • Z. Wiid

  • H. Jones

  • A. Szumski

  • L. Marshall

Medical Centers

  • University of Queensland School of Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia

  • Ghent University Hospital, Ghent, Belgium

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

Locations

  • United States

  • Belgium

  • Australia

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Non-radiographic axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Sacroiliitis

  • Inflammatory Arthritis

  • Axial spondyloarthritis

Biomarkers

  • Estrogen receptor alpha

  • Forkhead Box C1

  • High sensitivity C-reactive protein

Drug/Treatment

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved